Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States

John M. Boyle, Kenneth L. McCall, Stephanie D. Nichols, Brian J. Piper
doi: https://doi.org/10.1101/2020.11.30.20241182
John M. Boyle
1Department of Medical Education, Geisinger Commonwealth School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth L. McCall
2Department of Pharmacy Practice, University of New England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie D. Nichols
2Department of Pharmacy Practice, University of New England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Piper
1Department of Medical Education, Geisinger Commonwealth School of Medicine
3Center for Pharmacy Innovation and Outcomes, Precision Health Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: psy391@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose There have been increasing concerns about adverse effects and drug interactions with meperidine including removal from the World Health Organization’s list of essential medications. The goal of this study was to characterize pharmacoepidemiological patterns in meperidine use in the United States.

Methods Meperidine distribution data was obtained from the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS). Medicare Part D Prescriber Public Use Files (PUF) were utilized to capture overall trends in national meperidine prescriptions.

Results National meperidine distribution decreased from 2001 to 2019 by 94.6%. In 2019 Arkansas, Alabama, Oklahoma, and Mississippi saw significantly greater distribution per person when compared to the average state (9.27, SD = 6.82). Meperidine per ten persons showed an eighteen-fold difference between the highest (Arkansas = 36.8 mg) and lowest (Minnesota = 2.1 mg) states. Five of the six lowest states were in the northeast. Meperidine distribution per state was significantly correlated with the prevalence of adult obesity (r(47) = +0.47, p < 0.001).

Family medicine and internal medicine physicians accounted for 28.9% and 20.5% of Medicare Part D total daily supply (TDS) of meperidine in 2017. However, interventional pain management (5.66) and pain management (3.48) physicians accounted for the longest while family medicine (0.69) and internal medicine (0.40) accounted for the shortest TDS per provider.

Conclusion Use of meperidine has been declining over the last two-decades. Meperidine distribution varied on a geographical level with south/south-central, and more obese, states showing appreciably greater distribution per person. Primary care doctors continue to account for the majority of meperidine daily supply, but specialists like interventional pain management were the most likely to prescribe meperidine to Medicare patients. Increasing knowledge of meperidine’s undesirable adverse effects (e.g. seizures) and serious drug-drug interactions likely are responsible for these pronounced reductions.

Competing Interest Statement

BJP is part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no relevant disclosures.

Clinical Trial

This was not a clinical trial.

Funding Statement

The Geisinger Commonwealth School of Medicine Summer Research Immersion Program supported the summer stipend of the first author.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

#20180410-009

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* bpiper{at}som.geisinger.edu; psy391{at}gmail.com

  • Disclosures: BJP is part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no relevant disclosures.

Data Availability

Original data is available at the DEA's ARCOS and Medicare.

https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2019.pdf

https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted December 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States
John M. Boyle, Kenneth L. McCall, Stephanie D. Nichols, Brian J. Piper
medRxiv 2020.11.30.20241182; doi: https://doi.org/10.1101/2020.11.30.20241182
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States
John M. Boyle, Kenneth L. McCall, Stephanie D. Nichols, Brian J. Piper
medRxiv 2020.11.30.20241182; doi: https://doi.org/10.1101/2020.11.30.20241182

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Anesthesia
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (172)
  • Anesthesia (51)
  • Cardiovascular Medicine (456)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (160)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (192)
  • Epidemiology (5317)
  • Forensic Medicine (3)
  • Gastroenterology (199)
  • Genetic and Genomic Medicine (767)
  • Geriatric Medicine (81)
  • Health Economics (216)
  • Health Informatics (704)
  • Health Policy (364)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (166)
  • Infectious Diseases (except HIV/AIDS) (5971)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (107)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (781)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (147)
  • Occupational and Environmental Health (237)
  • Oncology (483)
  • Ophthalmology (155)
  • Orthopedics (40)
  • Otolaryngology (98)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (224)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (868)
  • Public and Global Health (2051)
  • Radiology and Imaging (356)
  • Rehabilitation Medicine and Physical Therapy (160)
  • Respiratory Medicine (288)
  • Rheumatology (96)
  • Sexual and Reproductive Health (75)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (30)
  • Urology (40)